What it does / how it works
A modified IGF-1 that stays free of binding proteins longer. It drives glucose into tissue and growth signals. Hypoglycaemia is the acute risk. Doses are in mcg, not mg.
| Class | Long-acting IGF-1 analogue |
| Typical vial | 0.1 or 1 mg |
| Reconstitution | 0.6% acetic acid (not plain water) |
| Storage after mix | 2–8°C, use within 28 days |
Protocol
| Goal | Dose | How often | How long | Route |
| Weeks 1-4 | 20 mcg | Once daily | 4 weeks | SubQ |
| Weeks 5-6 optional | 40-50 mcg | Once daily | 2 more weeks max | SubQ |
| Off | None | Stop | At least 4-6 weeks off | – |
Watch: A 1 mg vial is 20–50 microgram-range doses. WADA prohibited.